Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

30 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05381597 2025-11-28

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

Phase 2/3 Recruiting

200 enrolled

Gynecologic

Squamous Intraepithelial Lesions

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT05316467 2025-08-11

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Phase 2/3 Recruiting

89 enrolled

GynecologicOther

Infertility, Obesity, Endometrial Neoplasms, Overweight

NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Phase 2/3 Recruiting

80 enrolled

Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Phase 2/3 Recruiting

29 enrolled

GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Phase 2/3 Recruiting

296 enrolled

Gynecologic

Ovarian Cancer Recurrent

NCT06123884 2025-02-10

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Phase 2/3 Recruiting

526 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Gynecologic

Endometrial Neoplasms

NCT06288373 2024-10-30

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Phase 2/3 Recruiting

440 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

200 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05797831 2024-05-02

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Phase 2/3 Recruiting

268 enrolled

Gynecologic

Endometrial Neoplasms

NCT06341907 2024-04-02

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Phase 2/3 Recruiting

10 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT03458221 2023-04-18

STAPOVER

Phase 2/3 Recruiting

148 enrolled

Gynecologic

Ovarian Neoplasms, Neoplasms, Second Primary

NCT03463252 2021-09-13

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Phase 2/3 Recruiting

224 enrolled

Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

Clinical Trials

STOPGAP II

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

FEMUS

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Extended-field Proton Therapy for Cervical Cancer

ROCSAN

Trop2-targeted immunoPET Imaging of Solid Tumors

DETERMINE

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

DETERMINE

DETERMINE

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

RAINBO

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

STAPOVER

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC